CHO based biosimilar cell lines

Bioceros has developed a portfolio of high producing cell lines expressing biosimilar proteins, such as fusion proteins, enzymes and monoclonal antibodies which are available for out-licensing.

These biosimilar cell lines are generated on our proprietary CHO-based platform, CHOBC© using (animal component free) of the shelf culture medium. The cell lines are GMP-ready, stable, high producing, fully documented and functionally characterized. All available QA approved documentation is accessible for our (potential) partners via a Virtual Data Room.

Biosimilar programs that are completed and ready for tech transfer to a CMO of choice by our partner, as well as programs in different development stages, can be found in the table below.

For more information please contact J. Jansma at or call +31 88 9956 343

Biosimilar to



Cell lines available

Yervoy© BC017 Ipilimumab Ongoing
Perjeta© BC019 Pertuzumab Ongoing
Entyvio© BC020 Vedolizumab Ongoing
Herceptin© BC002REEM Trastuzumab
Humira© BC004 Adalimumab
Erbitux© BC005 Cetuximab
Avastin© BC006 Bevacizumab
Rituxan/MabThera© BC007 Rituximab
Enbrel© BC008 Etanercept
Synagis© BC009 Palivizumab
Xolair© BC011NPI Omalizumab
Myozyme© BC012 Alglucosidase alfa